India-based Lupin Ltd. launched its generic version of Allergan Plc's chewable oral contraceptive Minastrin 24 Fe March 16 but it’s getting unwelcome competition.
The same day Lupin announced its launch, Teva Pharmaceutical Industries Ltd. announced it had launched an authorized generic of Minastrin Fe.
Authorized generics are drugs sold under a license from the patent holder.
Although Lupin has 180 days of market exclusivity on the product—during which no other generics can come on the market—there’s an exception for authorized generics.
Teva’s launch is bound to affect the market potential for the Lupin product.
Brand companies frequently license authorized generics as a way to limit other generics’ market share. It’s not known yet how Lupin and Teva will price their products, and pricing is bound to affect how the market will respond to each company’s generic.
Elizabeth DeLuca, a spokesperson for Teva, told me Teva “will consider market dynamics and other relevant factors in establishing the price for this product.”
Lupin is going to market its generic under the name Mibelas 24 Fe but no one at the company was available to comment on the potential impact of Teva’s authorized generic launch on the outlook for Mibelas Fe.
Allergan’s Minastrin 24 Fe had annual sales of about $361 million in the U.S. in 2016, according to IMS figures.
Read my full story here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)